MONICA SAMUEL AVILA GRINBERG

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2018 ×

Resultados de Busca

Agora exibindo 1 - 10 de 10
  • conferenceObject
    Plasma Biomarkers Reflecting High Oxidative Stress Predicts Myocardial Injury Related to Anthracycline Chemotherapy in the CECCY Trial
    (2018) WANDERLEY JR., Mauro R.; AVILA, Monica S.; FERNANDES-SILVA, Miguel M.; CUNHA-NETO, Edecio; CRUZ, Fatima D.; BRANDAO, Goncalves Sara M.; RIGAUD, Vagner O.; HAJJAR, Ludhmila A.; KALIL FILHO, Roberto; BOCCHI, Edimar A.; AYUB-FERREIRA, Silvia M.
  • article 38 Citação(ões) na Scopus
    3rd Brazilian Directive on Cardiac Transplantation
    (2018) BACAL, Lemando; MARCONDES-BRAGA, Fabiana C.; ROHDE, Luis Eduardo Paim; XAVIER JUNIOR, Jose Leudo; BRITO, Flavio de Souza; MOURA, Lidia Ana Zytynski; COLAFRANCESCHI, Alexandre Siciliano; LAVAGNOLI, Carlos Fernando Ramos; GELAPE, Claudio Leo; ALMEIDA, Dirceu Rodrigues; GAIOTTO, Fabio Antonio; ATIK, Fernando Antibas; FIGUEIRA, Fernando Augusto M. S.; SOUZA, Germano Emilio Conceicao; RODRIGUES, Helcio; CAMPOS, Iascara Wozniak; SOUZA NETO, Joao David de; ROSSI NETO, Joao Manoel; GASPARETTO, Juliano; GOLDRAICH, Livia Adams; BENVENUTI, Luiz Alberto; SEGURO, Luis Fernando B. C.; ULHOA JUNIOR, Marcelo Boteiho; V, Maria da Consolacao Moreira; AVILA, Monica Samuel; CARNEIRO, Rodrigo; MANGINI, Sandrigo; FERREIRA, Silvia Moreira Ayub; STRABELLI, Tania Mara
  • bookPart
    Manejo de imunossupressores em emergência
    (2018) MENDES, Thiago Marques; SOLIS, Fernando Arturo Effio; AVILA, Mônica Samuel
  • conferenceObject
    Chagas' Disease Reactivation after Heart Transplant: Update on New Immunosuppression Era
    (2018) CAMPOS, I. W.; SEGURO, L. F.; ANDRADE, C. R.; MARCONDES-BRAGA, F. G.; SOARES, L. P.; AVILA, M. S.; MANGINI, S.; GALANTE, M. C.; GAIOTTO, F. A.; STRABELLI, T.; BACAL, F.
  • conferenceObject
    Vertebral fractures and bone metabolism impairment after heart transplant: results from a prospective cohort study
    (2018) SEGURO, L. F. B. C.; SEGURO, L. P. C.; MARCONDES-BRAGA, F. G.; CAPARBO, V. P.; TAKAYAMA, L.; MANGINI, S.; AVILA, M. S.; WOZNIAK, I.; GAIOTTO, F. A.; PEREIRA, R. M. R.; BACAL, F.
  • article 1 Citação(ões) na Scopus
    REPLY: Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity? A Dream to Be Balanced With Tolerability
    (2018) AVILA, Monica Samuel; FERREIRA, Silvia Moreira Ayub; BOCCHI, Edimar Alcides
  • bookPart
    Rejeição aguda de transplante cardíaco
    (2018) AULICINO, Gabriel Barros; AVILA, Mônica Samuel; BACAL, Fernando
  • article 343 Citação(ões) na Scopus
    Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
    (2018) AVILA, Monica Samuel; AYUB-FERREIRA, Silvia Moreira; WANDERLEY JR., Mauro Rogerio de Barros; CRUZ, Fatima das Dores; BRANDAO, Sara Michelly Goncalves; RIGAUD, Vagner Oliveira Carvalho; HIGUCHI-DOS-SANTOS, Marilia Harumi; HAJJAR, Ludhmila Abrahao; KALIL FILHO, Roberto; HOFF, Paulo Marcelo; SAHADE, Marina; FERRARI, Marcela S. M.; COSTA, Romulo Leopoldo de Paula; MANO, Max Senna; CRUZ, Cecilia Beatriz Bittencourt Viana; ABDUCH, Maria Cristina; ALVES, Marco Stephan Lofrano; GUIMARAES, Guilherme Veiga; ISSA, Victor Sarli; BITTENCOURT, Marcio Sommer; BOCCHI, Edimar Alcides
    BACKGROUND Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with beta-blockers remains controversial. OBJECTIVES This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m(2)) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a >= 10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction. RESULTS Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were noted between groups. A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). A nonsignificant trend toward a less-pronounced increase in LV end-diastolic diameter during the follow-up was noted in the carvedilol group (44.1 +/- 3.64 mm to 45.2 +/- 3.2 mm vs. 44.9 +/- 3.6 mm to 46.4 +/- 4.0 mm; p = 0.057). CONCLUSIONS In this largest clinical trial of beta-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the authors noted a 13.5% to 14.5% incidence of cardiotoxicity. In this scenario, carvedilol had no impact on the incidence of early onset of LVEF reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.(Carvedilol Effect in Preventing Chemotherap-Induced Cardiotoxicity [CECCy] NCTO1724450)(C) 2018 by the American College of Cardiology Foundation.
  • bookPart
    Rejeição aguda de transplante cardíaco
    (2018) AULICINO, Gabriel Barros; AVILA, Mônica Samuel; BACAL, Fernando
  • bookPart
    Manejo de imunossupressores em emergência
    (2018) MENDES, Thiago Marques; SOLIS, Fernando Arturo Effio; AVILA, Mônica Samuel